PUMA BIOTECHNOLOGY INC (PBYI) Stock Price, Forecast & Analysis
USA - NASDAQ:PBYI - US74587V1070 - Common Stock
PBYI Key Statistics, Chart & Performance
The current stock price of PBYI is 5.99 USD. In the past month the price increased by 16.99%. In the past year, price increased by 107.99%.
PBYI Latest News, Press Relases and Analysis
PBYI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.19 | 387.16B | ||
| AMGN | AMGEN INC | 14.64 | 172.38B | ||
| GILD | GILEAD SCIENCES INC | 14.51 | 147.46B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.59 | 104.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.61 | 69.69B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 868.04 | 58.03B | ||
| INSM | INSMED INC | N/A | 40.10B | ||
| NTRA | NATERA INC | N/A | 27.39B | ||
| BIIB | BIOGEN INC | 9.29 | 22.80B | ||
| INCY | INCYTE CORP | 16.51 | 20.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.01 | 20.30B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 36.45 | 15.11B |
Related stock screener links
About PBYI
Company Profile
Puma Biotechnology, Inc. is a biopharmaceutical company. The company is headquartered in Los Angeles, California and currently employs 172 full-time employees. The company went IPO on 2012-03-21. The firm is commercializing NERLYNX, an oral version of neratinib, for the treatment of certain HER2-positive breast cancers. NERLYNX is approved in the United States for two indications: the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy and for use in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. The firm has in-licensed and is responsible for the global development and commercialization of alisertib. The company intends to pursue the development of alisertib initially in small cell lung cancer and hormone receptor positive breast cancer.
Company Info
PUMA BIOTECHNOLOGY INC
10880 Wilshire Blvd., Suite 2150
Los Angeles CALIFORNIA 90024 US
CEO: Alan H. Auerbach
Employees: 172
Phone: 14242486500
PUMA BIOTECHNOLOGY INC / PBYI FAQ
Can you describe the business of PUMA BIOTECHNOLOGY INC?
Puma Biotechnology, Inc. is a biopharmaceutical company. The company is headquartered in Los Angeles, California and currently employs 172 full-time employees. The company went IPO on 2012-03-21. The firm is commercializing NERLYNX, an oral version of neratinib, for the treatment of certain HER2-positive breast cancers. NERLYNX is approved in the United States for two indications: the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy and for use in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. The firm has in-licensed and is responsible for the global development and commercialization of alisertib. The company intends to pursue the development of alisertib initially in small cell lung cancer and hormone receptor positive breast cancer.
Can you provide the latest stock price for PUMA BIOTECHNOLOGY INC?
The current stock price of PBYI is 5.99 USD. The price increased by 22.24% in the last trading session.
Does PBYI stock pay dividends?
PBYI does not pay a dividend.
What is the ChartMill technical and fundamental rating of PBYI stock?
PBYI has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
How is the market expecting PBYI stock to perform?
7 analysts have analysed PBYI and the average price target is 4.42 USD. This implies a price decrease of -26.21% is expected in the next year compared to the current price of 5.99.
Can you provide the market cap for PUMA BIOTECHNOLOGY INC?
PUMA BIOTECHNOLOGY INC (PBYI) has a market capitalization of 301.72M USD. This makes PBYI a Small Cap stock.
PBYI Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to PBYI. When comparing the yearly performance of all stocks, PBYI is one of the better performing stocks in the market, outperforming 96.1% of all stocks.
PBYI Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to PBYI. While PBYI has a great profitability rating, there are some minor concerns on its financial health.
PBYI Financial Highlights
Over the last trailing twelve months PBYI reported a non-GAAP Earnings per Share(EPS) of 0.74. The EPS increased by 54.17% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 20.35% | ||
| ROA | 24.86% | ||
| ROE | 46.27% | ||
| Debt/Equity | 0.1 |
PBYI Forecast & Estimates
7 analysts have analysed PBYI and the average price target is 4.42 USD. This implies a price decrease of -26.21% is expected in the next year compared to the current price of 5.99.
For the next year, analysts expect an EPS growth of -17.31% and a revenue growth -3.32% for PBYI